Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 3;30(5):221-230.
doi: 10.32604/or.2022.027549. eCollection 2022.

Utilization of kinase inhibitors as novel therapeutic drug targets: A review

Affiliations
Review

Utilization of kinase inhibitors as novel therapeutic drug targets: A review

Suchitra Nishal et al. Oncol Res. .

Abstract

Kinase inhibitors are a significant and continuously developing division of target therapeutics. The drug discovery and improvement efforts have examined numerous attempts to target the signaling pathway of kinases. The Kinase inhibitors have been heralded as a game-changer in cancer treatment. For developing kinase inhibitors as a treatment for various non-malignant disorders like auto-immune diseases, is currently undergoing extensive research. It may be beneficial to investigate whether cell-specific kinase inhibitor administration enhances therapeutic efficacy and decreases adverse effects. The goal of the current review is to gain insight into the role of kinase inhibitors in facilitating effective target drug delivery for the treatment of various anti-inflammatory, auto-immune, and anticancer disorders. The aim of this review is also to shed light on drug discovery approaches for kinase inhibitors, their mode of action, and delivery approaches. The variation in the binding of kinases bestows different target approaches in drug design, which can be employed for designing the targeted molecules. Several target sites have been studied, exceeding the design of drugs for various diseases like cancer, Alzheimer's, rheumatoid arthritis, etc. Diverse delivery approaches have also been studied for the targeted application of kinase inhibitors.

Keywords: Anti-cancer; Auto-immune diseases; Drug designing; Kinase inhibitors; Targeted.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest to report regarding the present study.

Figures

FIGURE 1
FIGURE 1. Expressing targets employed in the development of kinase inhibitors [7].
FIGURE 2
FIGURE 2. Describing the targets for kinase inhibitors for designing drug candidates.

References

    1. Kannaiyan, R., Mahadevan, D. (2018). A comprehensive review of protein kinase inhibitors for cancer therapy. Expert Review of Anticancer , 18(12), 1249–1270. DOI 10.1080/14737140.2018.1527688. - DOI - PMC - PubMed
    1. McGovern, S. L., Shoichet, B. K. (2003). Kinase inhibitors: Not just for kinases anymore. Journal of Medicinal Chemistry , 46(8), 1478–1483. DOI 10.1021/jm020427b. - DOI - PubMed
    1. Scheeff, E. D., Bourne, P. E. (2005). Structural evolution of the protein kinase-like superfamily. PLoS Computational Biology , 1(5), e49. DOI 10.1371/journal.pcbi.0010049. - DOI - PMC - PubMed
    1. Noble, M. E., Endicott, J. A., Johnson, L. N. (2004). Protein kinase inhibitors: Insights into drug design from structure. Science , 303(5665), 1800–1805. DOI 10.1126/science.1095920. - DOI - PubMed
    1. Li, T., Wang, N., Zhang, T., Zhang, B., Sajeevanet al. (2019). A systematic review of recently reported marine derived natural product kinase inhibitors. Marine Drugs , 17(9), 493. DOI 10.3390/md17090493. - DOI - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources